SAN FRANCISCO--(BUSINESS WIRE)-- Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that analysis performed by Mass General Hospital led by Kyle Staller, M.D., has been accepted for presentation at the upcoming ACG 2023 Scientific Meeting in Vancouver on October 24, 2023. The objectives of the analysis are intended to demonstrate that real world use of Mahana IBS leads to clinically meaningful reduction in IBS symptom severity as well as the factors predicting response and completion of the treatment.

“This is the largest analysis to date of our real world evidence of Mahana IBS covering a span of 2-years across all IBS subtypes. We look forward to unveiling results at ACG and thank our collaborators at Mass General Hospital who led our inaugural real-world evidence study,” said Simon Levy, CEO Mahana Therapeutics. “We anticipate that these results will further reinforce to the gastroenterology community the real world effectiveness of Mahana IBS in reducing symptom severity like pain and bloating experienced by so many patients suffering from IBS.”

The abstract presentation entitled “Efficacy of a Digital Prescription Mobile Application for Adults with Irritable Bowel Syndrome,” will be presented by Dr. Mythili Pathipati on Tuesday, October 24, 2023 at 8:30 AM during the Functional / Esophagus Plenary Session 2A.

About Mahana Therapeutics
Mahana Therapeutics is a leading developer of prescription digital therapeutics that are designed to empower patients with chronic conditions to live fuller lives. The company’s first product, Mahana IBS, was the first digital therapeutic to receive FDA clearance for the treatment of IBS and provides cognitive behavioral therapy (CBT) to adults with IBS. More information is available at www.mahana.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230912724101/en/